GlassScriptPhysician profile
Mikhail Grinberg
NPI 1013917400
$17,894.71
in general payments reported to CMS, 2019-2025
55 companies · $694 in 2025
The $694 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $1,961 · 2021: $6,017 · 2022: $3,571 · 2023: $300 · 2024: $3,422 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $1,222 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $1,221.97 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,950.00 | 2024 | Brukinsa |
| Kite Pharma, INC. | $1,716.35 | 2019-2022 | |
| Celgene Corporation | $1,587.99 | 2021-2022 | |
| Gilead Sciences, INC. | $1,395.12 | 2019-2022 | |
| Genentech USA, INC. | $1,382.55 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $1,363.68 | 2020-2022 | |
| Blueprint Medicines Corporation | $1,182.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,179.39 | 2020-2025 | Lynparza, Imfinzi, Calquence |
| Tesaro, INC. | $1,101.65 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $1,020.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $754.88 | 2019-2023 | |
| Amgen INC. | $412.80 | 2019-2022 | |
| Janssen Biotech, INC. | $324.22 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Astellas Pharma US INC | $179.48 | 2020-2024 | Xtandi |
| Pfizer INC. | $166.92 | 2019-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Grinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.